0.00 / 0.00%
Close in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 28 2015 17:15 BST.
IMM:LSE is traded on the London Stock Exchange Alternative Investment Market (Aim)


On Thursday, ImmuPharma PLC (IMM:LSE) closed at 48.50, 18.29% above the 52 week low of 41.00 set on Jun 09, 2014.

52-week range
Jun 09 2014
Nov 03 2014
Day high--
Day low--
Previous close48.50
Average volume61.60k
Shares outstanding88.62m
Free float42.19m
P/E (TTM)--
Market cap42.98m GBP
EPS (TTM)-0.0345 GBP
Data delayed at least 15 minutes, as of May 28 2015 17:15 BST.

RNS Company announcements

Annual Report & Accounts
Interim Board Change
Directorate Change
Preliminary Results

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
ImmuPharma PLC+1.04 %-5.83 %-14.91 %0.00%-38.61 %
FTSE 100 IDX+0.39 %+0.15 %+4.72 %+2.77 %+35.70 %
GB/HEALTH CARE+1.42 %-1.65 %+1.24 %+5.99 %+37.30 %
GB/PHARMACEUTICALS+1.34 %-1.86 %+0.99 %+5.40 %+36.67 %
Data delayed at least 15 minutes, as of May 28 2015 17:15 BST.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.